



Test Definition: HIBC

Histoplasma/Blastomyces Panel, Spinal Fluid

Overview

Useful For

Aiding in the diagnosis of histoplasmosis or blastomycosis meningitis

Profile Information

Test Id	Reporting Name	Available Separately	Always Performed
HICSF	Histoplasma Ab CompFix/ImmDiff, CSF	Yes	Yes
CBL	Blastomyces Ab Immunodiffusion, CSF	Yes	Yes

Testing Algorithm

For information see [Meningitis/Encephalitis Panel Algorithm](#)

Special Instructions

- [Meningitis/Encephalitis Panel Algorithm](#)

Method Name

HICSF: Complement Fixation (CF)/Immunodiffusion (ID)

CBL: Immunodiffusion (ID)

NY State Available

Yes

Specimen

Specimen Type

CSF

Specimen Required

Container/Tube: Sterile vial

Specimen Volume: 1.5 mL

Collection Instructions: Submit specimen from collection vial number 1.

Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
CSF	Refrigerated (preferred)	14 days	
	Frozen	14 days	

Clinical & Interpretive

Clinical Information

Histoplasma

Histoplasma capsulatum is a dimorphic fungus endemic to the Midwestern United States, particularly along the Mississippi and Ohio river valleys. Infection occurs following inhalation of fungal microconidia, and subsequent clinical manifestations are largely dependent on the fungal burden at the time of exposure and the patient's underlying immune status. While the vast majority (>90%) of exposed individuals will remain asymptomatic, those seeking medical attention can present with a diverse set of symptoms ranging from a self-limited pulmonary illness to severe, disseminated disease. Individuals at risk for severe infection include those with impaired cellular immunity, who have undergone organ transplantation, who are HIV positive, or who have a hematologic malignancy.

The available laboratory methods for the diagnosis of *H capsulatum* infection include fungal culture, molecular techniques, serologic testing, and antigen detection. While culture remains the gold standard diagnostic test and is highly specific, prolonged incubation is often required, and sensitivity decreases (9%-34%) in cases of acute or localized disease. Similarly, molecular methods offer high specificity but decreased sensitivity. Serologic testing likewise offers high specificity; however, results may be falsely negative in immunosuppressed patients or those who present with acute disease. Also, antibodies may persist for years following disease resolution, thereby limiting the clinical specificity.

Blastomyces

Blastomyces dermatitidis is endemic throughout the Midwestern, South Central, and Southeastern United States, particularly in regions around the Ohio and Mississippi river valleys, the Great Lakes, and the Saint Lawrence River. It is also found in regions of Canada. *Blastomyces* species are dimorphic fungi, preferring moist soil and decomposing organic matter, which produces fungal spores that are released and inhaled by humans. At body temperature, spores mature into yeast, which may remain in the lungs or disseminate through the bloodstream to other parts of the body. Through phylogenetic analysis, *B dermatitidis* has been separated into 2 distinct species: *B dermatitidis* and *Blastomyces gilchristii*, both able to cause blastomycosis. *B dermatitidis* infections are frequently associated with dissemination, particularly in older patients, smokers, and immunocompromised hosts, while *B gilchristii* has primarily been associated with pulmonary and constitutional symptoms. Additional species of *Blastomyces* have recently been discovered and characterized, however the performance characteristics of this assay for these species are unknown.

Approximately half of patients infected with *Blastomyces* will develop symptoms that are frequently nonspecific, including fever, cough, night sweats, myalgia or arthralgia, weight loss, dyspnea, chest pain, and fatigue. Symptoms may appear anywhere from 3 weeks to 3 months following infection. Diagnosis of blastomycosis relies on a combination of assays, including culture and molecular testing performed on appropriate specimens, and serologic evaluation for both antibodies to and antigen released from *Blastomyces*. Although culture remains the gold standard method and is highly specific, the organism can take several days to weeks to grow and sensitivity is diminished in cases of acute or localized disease. Similarly, molecular testing offers high specificity and a rapid turnaround time, however sensitivity is imperfect. Detection of an antibody response to *Blastomyces* offers high specificity, however results may be falsely negative in patients who are acutely ill or immunosuppressed.

Reference Values**HISTOPLASMA ANTIBODY**

Anti-Yeast antibody by Complement Fixation: Negative

Antibody by Immunodiffusion: Negative

BLASTOMYCES ANTIBODY IMMUNODIFFUSION

Negative

Interpretation*Histoplasma:*

Any positive serologic result in spinal fluid is significant.

Blastomyces:

Any positive result in spinal fluid is significant.

Cautions

Results cannot distinguish between active disease and prior exposure.

Detection of antibodies in spinal fluid (CSF) may reflect intrathecal antibody production or they may be present due to passive transfer or introduction of antibodies from the blood during lumbar puncture.

Routine fungal culture of clinical specimens (eg, CSF) is recommended in cases of suspected blastomycosis involving the central nervous system.

Histoplasma:-Antibody levels may be low in spinal fluid in cases of *Histoplasma* meningitis.

-Cross-reacting antibodies with coccidioidomycosis or blastomycosis may cause false-positive results for histoplasmosis.

Blastomyces:

-A negative result does not rule out blastomycosis.

-Patients with histoplasmosis may have low-titered cross reactions.

Clinical Reference

1. Kaufman L, Kovacs JA, Reiss E: Clinical immunomycology. In: Rose NL, Conway-de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of Clinical Laboratory Immunology. ASM Press; 1997:588-589
2. Gauthier GM, Klein BS: Blastomycosis. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:3177-3189
3. Deepe GS: *Histoplasma capsulatum* Histoplasmosis. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:3162-3176
4. Theel ES, Kus JV, Grys TE, Ampel NM, Schwartz IS, Zhang SX. Practical Guidance for Clinical Microbiology Laboratories: Antibody and antigen detection methods for dimorphic fungal infections. Clin Microbiol Rev. 2025;38(2):e0000520. doi:10.1128/cmr.00005-20

Performance

Method Description

Histoplasma

Both immunodiffusion (ID) and complement fixation (CF) tests are used to detect antibodies to *Histoplasma capsulatum*. For ID, the antigen is a culture filtrate, histoplasmin. H and M precipitin bands are identified. For the CF test, the antigens are histoplasmin and a yeast form of *H capsulatum*; the latter is more sensitive. (Roberts GD: Fungi. In: Washington II JA, ed. Laboratory Procedures in Clinical Microbiology. 2nd ed. Springer-Verlag, 1985; In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020)

Blastomyces

The ID test is a qualitative test employed for the detection of precipitating antibodies present in the specimen. Soluble antigens of the fungus are placed in wells of an agarose gel-filled Petri dish, and the patient's specimen and a control (positive) are placed in adjoining wells. If present, specific precipitate antibody will form precipitin lines between the wells. Their comparison to the control establishes the results. When performing the ID test, only precipitin bands of identity with the reference bands are significant. (Kaufman L, McLaughlin DW, Clark MJ, Blumer S: Specific immunodiffusion test for blastomycosis. Appl Microbiol. 1973;26:244-247, Williams JE, Murphy R, Standard PG, Phan JP: Serologic response in blastomycosis: diagnostic value of double immunodiffusion assay. Am Res Resp Dis. 1981;123:209-212; Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020)

PDF Report

No

Day(s) Performed

Monday through Friday

Report Available

3 to 7 days

Specimen Retention Time

14 days

Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Superior Drive

Fees & Codes

Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86698 x2

86612

LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
HIBC	Histoplasma/Blastomyces Panel, CSF	91683-3

Result ID	Test Result Name	Result LOINC® Value
15134	Blastomyces Immunodiffusion (CSF)	51741-7
621217	Histoplasma Yeast CompFix, CSF	27209-6
621218	Histoplasma Immunodiffusion, CSF	91682-5